Brett Dolgin, DO
Procedural Dermatology · Great Neck, NYNPI 1417206459
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 995 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,622, 2.1 times the $2,155 reported in 2019.
Across 995 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Novartis$2K
- Arcutis Biotherapeutics, Inc.$2K
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$1K
- LEO Pharma Inc.$1K
- plus $9K from 31 others
What the payments were for
- Food & beverage$19,68398%
- Education$4852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 109 | $2,844 |
| Novartis | 191 | $2,401 |
| Arcutis Biotherapeutics, Inc. | 36 | $2,135 |
| AbbVie | 79 | $1,552 |
| Sun Pharmaceutical Industries Inc. | 56 | $1,342 |
| LEO Pharma Inc. | 57 | $1,272 |
| UCB, Inc. | 43 | $938 |
| Lilly USA, LLC | 51 | $911 |
| Dermavant Sciences, Inc. | 57 | $859 |
| Regeneron Healthcare Solutions, Inc. | 37 | $853 |
| Galderma Laboratories, L.p. | 58 | $848 |
| Incyte Corporation | 46 | $778 |
| Sanofi | 37 | $716 |
| Pfizer | 26 | $522 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 34 | $521 |
| Amgen | 15 | $383 |
| Boehringer Ingelheim | 9 | $230 |
| Biofrontera Inc. | 7 | $118 |
| Journey Medical Corporation | 7 | $113 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Dermira, Inc. | 4 | $99 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $85 |
| Organon | 8 | $65 |
| Genentech USA, Inc. | 4 | $61 |
| Paratek Pharmaceuticals, Inc. | 3 | $60 |
| Bristol Myers Squibb | 3 | $56 |
| Verrica Pharmaceuticals Inc. | 2 | $52 |
| Mayne Pharma Commercial LLC | 2 | $43 |
| Kyowa Kirin, Inc. | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $33 |
| DUSA Pharmaceuticals, Inc. | 1 | $21 |
| Botanix SB Inc | 1 | $21 |
| Almirall LLC | 1 | $16 |
| LNHC, Inc | 1 | $16 |
| Merck | 1 | $13 |
| Strata Skin Sciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZORYVE$1,012
How this compares
$20,168 in reported general payments places this provider in the 75th percentile of 69 procedural dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 48 | $627,206 |
| Skyrizi PenRisankizumab-Rzaa | 29 | $570,766 |
| Dupixent PenDupilumab | 84 | $340,013 |
| OtezlaApremilast | 35 | $248,093 |
| Doxycycline Ir-DrDoxycycline Monohydrate | 20 | $30,606 |
| ZoryveRoflumilast | 13 | $10,880 |
| Pimecrolimus | 30 | $10,553 |
| Metronidazole | 107 | $5,483 |
| Tacrolimus | 33 | $4,397 |
| Ketoconazole | 192 | $3,983 |
| Doxycycline Hyclate | 106 | $3,872 |
| Fluorouracil | 63 | $3,825 |
| Triamcinolone Acetonide | 163 | $2,293 |
| Clobetasol Propionate | 38 | $2,019 |
| Tretinoin | 21 | $1,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $2,844 | $627,20648 claims |
| AmgenOtezla | $383 | $248,09335 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $2,135 | $10,88013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 69 procedural dermatology providers in New York.
Other procedural dermatology in Great Neck
- Nancy WolfinGreat Neck$13K
- Adam BodianGreat Neck$12K
- Joseph SchwartzTroy$470K
- Michelle HenryNew York$460K
- Jerry ShapiroNew York$414K
- Jared JagdeoBrooklyn$362K
- Dendy EngelmanNew York$292K
- Evan RiederNew York$210K
- Daniel Belkin-HollandNew York$208K
- Suzanne Sirota-RozenbergWoodmere$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.